Fabien Gueugnon is in charge of the pre-clinical development of new Vaxeal’s immunotherapies. He is an immunologist with a strong expertise in immuno-oncology, animal experimentation, and translational studies. Before joining Vaxeal in 2016, Fabien was Research Associate in the Research Centre for Respiratory Diseases (CEPR, Inserm U1100) where he worked on projects dedicated to show the involvement of certain proteases in lung pathologies (Cancer, COPD and Flu). Before that, as Postdoctoral fellow in the Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA, Inserm U1232), he conducted basic and translational studies related to lung cancer/mesothelioma and focusing on the improvement of diagnosis (biomarkers discovery and validation) and treatment efficiency (modulation of immune response by anticancer drugs).Fabien holds a Master’s degree in Cellular Biology and Physiology and a PhD in Biochemistry, Cellular and Molecular Biology from the University of Burgundy (Dijon, France).
Vaxeal’s highly experienced executive team has an extensive track record in company management, immunotherapy product development and regulatory compliance. The Board also brings a wealth of diverse corporate and M&A experience.
Vaxeal’s pre-eminent Scientific Advisory Board advises the company in the fields of immunology, immunotherapy, clinical immuno-oncology, infectious diseases and regulatory affairs.